Winter 2017/18 Teasers
Page 1 to 9 of 9 |
New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann
Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development.

Read More

Technology innovation will help prepare drug discovery for smart screening era By Dr Clive Green and Dr Philip Spencer
Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds.

Read More

Emerging drug discovery alliance models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker
The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging.

Read More

Automating flow cytometry for cell-based screening in drug discovery By Paul Avery & Richard Massey
Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications.

Read More

Breaking down silos in drug development - why interdisciplinary integration is fundamental for pharma’s future By Dr Paul Overton
A silo mentality is an issue for any organisation, but it is particularly problematic for the pharmaceutical industry.

Read More

Discovery and development of inhaled biopharmaceuticals - The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall
With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater in terms of helping the drug discovery community as a whole.

Read More

Practicalities of conducting REPLICATION STUDIES By Dr Nicole Perfito, Dr Rachel Tsui & Dr Elizabeth Iorns
The first results for the Reproducibility Project: Cancer Biology offer insights into the time and cost of conducting replication studies in preclinical cancer biology.

Read More

High-throughput spheroid culture By Hilary Sherman, Dr Richard M. Eglen & Audrey Bergeron
The cost of drug development is becoming unsustainable, partly due to the high attrition rate of drugs in clinical trials.

Read More

Use of Next-Generation Sequencing in the regulated domain of drug development By Keith Nangle & Mike Furness
Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making.

Read More

Winter 2017/18 Teasers
Page 1 to 9 of 9 |